Alaunos Therapeutics, Inc. (TCRT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TCRT currently has 24.4M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 978.69% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 24.4M shares outstanding |
24M | 0 |
| Mar 31, 2026 |
10-K filing | 2.4M shares outstanding |
2.4M | 180K |
| Nov 14, 2025 |
10-Q filing | 2.2M shares outstanding |
2.2M | 380K |
| Nov 07, 2025 |
S-3/A filing: SEC filing for Alaunos Therapeutics, Inc. detailing a potential offering of common stock, preferred stock, and debt securities up to $50,000,000, as well as the registration for resale of common stock issuable upon conversion of preferred stock. |
2.3M | 240K |
| Aug 14, 2025 |
10-Q filing | 2.2M shares outstanding |
2.2M | 0 |
| Jun 26, 2025 |
8-K filing: Alaunos Therapeutics, Inc. completed a registered direct offering on June 24, 2025, issuing 338,725 shares of common stock at $3.36 per share and 271,674 pre-funded warrants at $3.359 per share. |
1.6M | 510K |
| Jun 26, 2025 |
8-K filing: Alaunos Therapeutics, Inc. entered into a Subscription Agreement to issue and sell Series A-2 Convertible Preferred Stock for an aggregate purchase price of $850,000 in a private offering that closed on June 24, 2025. ($0.85M proceeds) |
1.6M | 510K |
| Jun 10, 2025 |
8-K filing: Alaunos Therapeutics, Inc. amended a warrant agreement with Mast Hill Fund, L.P. on June 9, 2025, modifying the terms related to the exercise price and share adjustments in the event of dilutive issuances, variable price adjustments, and fundamental transactions. |
1.6M | 510K |
| May 23, 2025 |
8-K filing: Alaunos Therapeutics, Inc. entered into an equity purchase agreement with Mast Hill Fund, L.P., where Mast Hill committed to purchase up to $25.0 million of the Company's common stock; also, the Company issued a warrant to Mast Hill to purchase 79,900 shares of common stock. |
1.6M | 510K |
| May 15, 2025 |
10-Q filing | 1.6M shares outstanding |
1.6M | 510K |
| Apr 14, 2025 |
8-K filing: Alaunos Therapeutics, Inc. entered into a Subscription Agreement to issue and sell Series A-1 Convertible Preferred Stock at $1,000 per share for an aggregate purchase price of $500,000, which offering closed on April 11, 2025. ($0.5M proceeds) |
1.6M | 510K |
| Mar 31, 2025 |
10-K filing | 1.6M shares outstanding |
1.6M | 510K |
| Nov 14, 2024 |
10-Q filing | 1.6M shares outstanding |
1.6M | 510K |
| Aug 14, 2024 |
10-Q filing | 1.6M shares outstanding |
1.6M | 510K |
| Jul 17, 2024 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 16,012,522 → 1,601,252 |
1.6M | 0 |
| May 15, 2024 |
10-Q filing | 16.0M shares outstanding |
16M | 5.1M |
| Apr 01, 2024 |
10-K filing | 16.0M shares outstanding |
16M | 5.2M |
| Jan 31, 2024 |
Stock Split
8-K filing: Stock split 1-for-15 | Outstanding: 240,046,026 → 16,003,068 |
16M | 0 |
| Nov 14, 2023 |
10-Q filing | 240.0M shares outstanding |
240M | 77M |
| Aug 14, 2023 |
10-Q filing | 239.8M shares outstanding |
240M | 77M |
| May 10, 2023 |
10-Q filing | 239.7M shares outstanding |
240M | 78M |
| Mar 07, 2023 |
10-K filing | 217.1M shares outstanding |
220M | 100M |
| Nov 14, 2022 |
10-Q filing | 215.1M shares outstanding |
220M | 100M |
| Aug 31, 2022 |
S-3/A filing: The filing is an S-3/A form indicating that the company may offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, and debt securities, either individually or in combination. |
220M | 100M |
| Aug 15, 2022 |
10-Q filing | 215.0M shares outstanding |
210M | 28M |
| Aug 12, 2022 |
S-3 filing: The filing is for an S-3 registration statement to offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, and debt securities, either individually or in combination, from time to time, and also for an at-the-market offering of common stock with an aggregate offering price of up to $50,000,000 through Piper Sandler. |
220M | 27M |
| May 16, 2022 |
10-Q filing | 216.0M shares outstanding |
220M | 0 |
| Mar 30, 2022 |
10-K filing | 214.4M shares outstanding |
210M | 0 |
| Nov 08, 2021 |
10-Q filing | 216.1M shares outstanding |
220M | 0 |
| Aug 13, 2021 |
10-Q filing | 215.6M shares outstanding |
220M | 0 |
| May 06, 2021 |
10-Q filing | 215.5M shares outstanding |
220M | 0 |
| Mar 01, 2021 |
10-K filing | 209.6M shares outstanding |
210M | 0 |
| Nov 05, 2020 |
10-Q filing | 214.3M shares outstanding |
210M | 0 |
| Aug 06, 2020 |
10-Q filing | 214.2M shares outstanding |
210M | 0 |
| May 07, 2020 |
10-Q filing | 214.3M shares outstanding |
210M | 0 |
| Mar 02, 2020 |
10-K filing | 213.0M shares outstanding |
210M | 0 |